Ultragenyx reports serious adverse effects in gene therapy trial (NASDAQ:RARE)

Published on 15 Apr 2024 on Seeking Alpha

Shares of Ultragenyx Pharmaceutical (RARE) dropped 7% after serious adverse effects were reported in...

Read the rest of the article

Start tracking your investments with Statfolio

Rare disease therapies are extremely expensive, with some costing millions of dollars. They are...

Seeking Alpha 16 Apr 2024

Ultragenyx Pharmaceutical Inc. RARE reported positive interim data from the expansion cohorts of ...

Zacks via Yahoo Finance 16 Apr 2024

Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharply during Monday’s session after the co...

Benzinga 15 Apr 2024

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Mond...

Benzinga 15 Apr 2024

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Mond...

Benzinga 15 Apr 2024

Shares of Ultragenyx Pharmaceutical (RARE) dropped 7% after serious adverse effects were reported...

Seeking Alpha 15 Apr 2024

Investing.com 15 Apr 2024

On Monday, Stifel reiterated its Buy rating on shares of Ultragenyx Pharmaceutical Inc....

Investing.com 15 Apr 2024

Director Matthew Fust has sold 12,195 shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Ma...

GuruFocus.com via Yahoo Finance 11 Mar 2024

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript February 15, 2024 U...

Insider Monkey via Yahoo Finance 16 Feb 2024